Skip to content
AnalystLens

Idex 8-K Report, Financial Results (Oct 30, 2024)

Reports
Earnings & Results·Regulation FD·Exhibits & Filings
Filing Date
Filed October 30, 2024
Period End
October 29, 2024
Security
IEX
In the record · 2016–202610-K1110-Q338-K119

IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Jan ’18Jan ’18
  2. Material agreement8-K · Apr ’20Apr ’20
  3. Leadership change8-K · Sep ’22Sep ’22
  4. Material agreement8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed October 30, 2024. Cited figures are marked; the original filing is the authoritative source.

IDEX Corporation (NYSE: IEX) reported third-quarter 2024 results in a press release dated October 29, 2024, furnished with this Form 8-K.

Net sales were $798.2 milliona, up 1% overall and flat on an organic basis, with lower volumes in the Health & Science Technologies segment offset by price capture. Orders rose to $780.5 million from $712.3 million, and organic orders increased 8%. Reported diluted EPS fell to $1.57 from $2.75, down 43%, mainly because the prior-year period included the gain on the sale of the Micropump business.

Adjusted diluted EPS was $1.90b, down 10%, and adjusted EBITDA margin was 26.9%, down 150 bps, as higher employee-related costs and lower volume outweighed price/cost gains. Operating cash flow was $205.3 million, down 9%, and free cash flow was $191.6 million, down 7%. The company completed its acquisition of Mott Corporation on September 5, 2024, for cash consideration of $986.2 million, net of $3.1 million of cash acquired.

IDEX states that the net transaction value, after the present value of expected tax benefits of approximately $100 millionc, is about $900 million, or roughly 19x Mott's forecasted full-year 2024 EBITDA. The company expects the acquisition to be accretive to adjusted earnings per share in fiscal 2026. During the quarter, IDEX also completed a public offering of $500 million principal amount of 4.950% Senior Notes due September 2029.

For full-year 2024, IDEX projects organic sales to decline 1% to 2%. It raised the low end of its adjusted diluted EPS guidance to $7.85 to $7.90d from $7.80 to $7.90, and lowered its GAAP diluted EPS guidance to $6.65 to $6.70 from $6.85 to $6.95.

The company attributes the GAAP change to purchase accounting impacts, including acquisition-related amortization from Mott. Management stated that segment-level orders and backlog trends, particularly in Health & Science Technologies, will be key indicators to watch as the company looks for signs of recovery in life science and semiconductor markets.

Key Highlights

  1. Net sales of $798.2 million rose 1% year over year, but organic net sales were flat, with price capture offsetting lower volumes in Health & Science Technologies.
  2. Orders increased to $780.5 million from $712.3 million, with organic orders up 8%.
  3. Reported diluted EPS fell 43% to $1.57, mainly because the prior-year period included the gain on the Micropump divestiture; adjusted diluted EPS declined 10% to $1.90.
  4. Adjusted EBITDA margin was 26.9%, down 150 bps, as higher employee-related costs and lower volume outweighed price/cost gains.
  5. Operating cash flow of $205.3 million declined 9%, and free cash flow of $191.6 million declined 7%.
  6. The Mott Corporation acquisition closed September 5, 2024, for $986.2 million in cash (net of $3.1 million cash acquired), with a net transaction value of about $900 million after tax benefits; IDEX expects it to be accretive to adjusted EPS in fiscal 2026.
  7. Full-year 2024 guidance projects organic sales decline of 1% to 2%, adjusted diluted EPS of $7.85 to $7.90, and GAAP diluted EPS of $6.65 to $6.70.

Frequently Asked Questions

  1. Why did reported diluted EPS decline so sharply in the third quarter?

    Reported diluted EPS of $1.57 was down 43% from $2.75 in the prior-year period. The filing attributes the decline primarily to the absence of the gain on the sale of the Micropump business in the prior year, along with lower operating results and a higher effective tax rate. The prior-year period also had one-time tax benefits that lowered its effective tax rate.

  2. How did the Mott Corporation acquisition affect the company's financial profile?

    IDEX paid $986.2 million in cash, net of $3.1 million of cash acquired, for Mott on September 5, 2024. After the present value of expected tax benefits of approximately $100 million, the net transaction value is about $900 million, roughly 19x Mott's forecasted full-year 2024 EBITDA. The company expects the deal to be accretive to adjusted EPS in fiscal 2026. Third-quarter results include $3.7 million of higher transaction-related expenses tied to the acquisition.

  3. What is the company's full-year 2024 outlook?

    IDEX projects full-year organic sales to decline 1% to 2% versus the prior year. Adjusted diluted EPS guidance is $7.85 to $7.90, compared with the prior $7.80 to $7.90. GAAP diluted EPS guidance was lowered to $6.65 to $6.70 from $6.85 to $6.95, which the company attributes to purchase accounting impacts from the Mott acquisition. The company expects a tax rate of approximately 22% for the full year.

  4. Which business segments drove performance, and which were weaker?

    Fire & Safety/Diversified Products reported net sales up 4% with organic growth also up 4%, and the filing describes record sales despite cyclical weakness in North American dispensing. Fluid & Metering Technologies reported flat net sales with organic sales up 2%, though its adjusted EBITDA margin fell 160 bps. Health & Science Technologies reported flat net sales with organic sales down 5%, reflecting broad-based market softness, although its orders rose 20% organically.